Holestatin (Rosuvastatin Calcium)

Holestatin is indicated for the treatment of several lipid disorders and for reducing cardiovascular risk in patients with elevated cholesterol. It is used as part of a comprehensive management plan that includes diet, exercise, and lifestyle modification.

• Primary hypercholesterolemia (high LDL‑cholesterol)
• Mixed dyslipidemia (elevated LDL and triglycerides)
• Familial hypercholesterolemia
• Prevention of cardiovascular events in patients at risk
• Secondary prevention after myocardial infarction or stroke

• Rosuvastatin calcium selectively inhibits HMG‑CoA reductase, the rate‑limiting enzyme in the hepatic synthesis of cholesterol. This inhibition reduces intracellular cholesterol production, leading to up‑regulation of LDL receptors on hepatocyte surfaces and increased clearance of LDL particles from the bloodstream, thereby lowering plasma LDL‑cholesterol and total cholesterol levels.

Like other statins, rosuvastatin may cause a range of adverse reactions, most of which are mild and reversible, while rare events can be serious.

Common

• Muscle pain, tenderness, or weakness, often mild and transient.
• Headache, ranging from mild to moderate intensity.
• Nausea, vomiting, or abdominal discomfort, usually short‑lived.
• Mild, asymptomatic elevations in liver enzymes detected on routine testing.

Serious

• Rhabdomyolysis, characterized by severe muscle breakdown and possible kidney impairment.
• Significant liver injury with marked increases in transaminases or bilirubin.
• Severe allergic reactions, including angioedema, urticaria, or anaphylaxis.

Before starting Holestatin, clinicians should evaluate patient history and monitor specific parameters to minimize risks. Patients with certain medical conditions or concomitant therapies may require dose adjustment or closer observation.

• Assess liver function before initiation and periodically during therapy.
• Screen for muscle disorders or a history of rhabdomyolysis.
• Use caution in patients with renal impairment; dose may need adjustment.
• Evaluate pregnancy status; statins are generally contraindicated during pregnancy.
• Monitor for diabetes onset or worsening glycemic control.
• Consider drug interactions with CYP2C9 substrates.

Rosuvastatin can interact with several medicines, affecting its concentration or increasing the risk of adverse events.

Avoid

• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone).
• Cyclosporine or other potent OATP1B1 inhibitors.
• High‑dose niacin combined with statins.

Use with caution

• Anticoagulants such as warfarin (may increase INR).
• Fibrates (gemfibrozil) – higher risk of muscle toxicity.
• Certain antiretrovirals (e.g., protease inhibitors).